

Transcranial random noise stimulation for the acute treatment of depression: a randomized controlled trial

Stevan Nikolin, Ph.D.^{1,2*}, Angelo Alonzo, Ph.D.^{1,2}, Donel Martin, Ph.D.^{1,2}, Veronica Gálvez, MD.^{1,3}, Sara Buten, MD.^{1,4}, Rohan Taylor, MD.^{1,5}, James Goldstein, MD.⁶, Cristal Oxley, MD.⁷, Dusan Hadzi-Pavlovic, BSC.¹, Prof Colleen K. Loo, MD.^{1,2,8}

¹ School of Psychiatry, University of New South Wales, Sydney, Australia

² Black Dog Institute, Sydney, Australia

³ Mental Health Department, Parc Taulí University Hospital, Institut d'Investigació I

Innovació Sanitària Parc Taulí (I3PT), Barcelona, Spain

⁴ Prince of Wales Hospital, Sydney, Australia

⁵ Concord Centre for Mental Health, Concord, Australia

⁶ Currumbin Clinic, Currumbin, Australia

⁷ Department of Child and Adolescent Psychiatry, Michael Rutter Centre – South London and

Maudsley NHS Foundation Trust, UK

⁸ St. George Hospital, Sydney, Australia

*Corresponding Author

Email. stevan.nikolin@unsw.edu.au

Address: Black Dog Institute, Hospital Road, Randwick 2031 NSW, Australia

Phone: +61 2 9385 8513

Funding

NHMRC project grant APP1051423

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

24 **Abstract**

25 **Background**

26 Transcranial electrical stimulation has broad potential as a treatment for depression.
27 Transcranial random noise stimulation (tRNS), which delivers randomly fluctuating current
28 intensities, may have greater cortical excitatory effects compared to other forms of
29 transcranial electrical stimulation. We therefore aimed to investigate the antidepressant
30 efficacy of tRNS.

31 **Methods**

32 Depressed participants were randomly assigned by computer number generator to receive 20
33 sessions of either active or sham tRNS over four weeks in a double-blinded, parallel group
34 randomized-controlled trial. tRNS was delivered for 30mins with a direct current offset of
35 2mA and a random noise range of 2mA. Primary analyses assessed changes in depression
36 severity using the Montgomery-Asperg Depression Rating Scale (MADRS). Neuroplasticity,
37 neuropsychological, and safety outcomes were analysed as secondary measures.

38 **Results**

39 69 participants were randomised, of which three discontinued treatment early leaving 66
40 (sham n = 34, active n = 32) for per-protocol analysis. Depression severity scores reduced in
41 both groups (MADRS reduction in sham = 7.0 [95%CI 5.0-8.9]; and active = 5.2 [95%CI
42 3.2-7.3]). However, there were no differences between active and sham groups in the
43 reduction of depressive symptoms, or the number of participants meeting response (sham =
44 14.7%; active = 3.1%) and remission criteria (sham = 5.9%; active = 0%). Erythema,
45 paraesthesia, fatigue, and dizziness/light-headedness occurred more frequently in the active
46 tRNS group. Neuroplasticity, neuropsychological and acute cognitive effects were
47 comparable between groups.

48 **Conclusion**

49 Our results do not support the use of tRNS with the current stimulation parameters as a
50 therapeutic intervention for the treatment of depression.

51 Clinical trial registration at clinicaltrials.gov/NCT01792414.

52

53 **Significance Statement**

54 This is the first randomized sham-controlled clinical trial of a four-week course of
55 transcranial random noise stimulation (tRNS) for the treatment of depression. tRNS is a
56 relatively novel form of non-invasive electrical stimulation that uses mild, randomly
57 fluctuating currents to constrain homeostatic mechanisms and increase brain excitability. We
58 investigated effects across multiple validated mood outcomes and comprehensively assessed
59 cognitive, neurophysiological, and physical side effects to examine the safety of tRNS. We
60 found no differences between active and sham conditions for all mood outcomes, and are thus
61 unable to lend support for tRNS as an effective treatment for depression. We found tRNS to
62 be well-tolerated with no adverse acute cognitive, neuropsychological or severe physical side
63 effects, suggesting a course of 20 repeated sessions can be delivered safely.

64 Introduction

65 Although there are a number of established treatments for depression, a sizeable
66 proportion of patients still fail to adequately respond, with a conservative estimate of
67 approximately one-third of these not reaching remission even after four trials of different
68 antidepressant medication classes (A J Rush et al., 2006b). In addition, many patients fail to
69 complete a course of antidepressants due to side effects (A John Rush et al., 2006a; Trivedi et
70 al., 2006). While electroconvulsive therapy (ECT) remains the most effective treatment, with
71 response rates of up to 70% (Haq et al., 2015), treatment uptake and adherence can be limited
72 by patient concerns over possible cognitive side effects and the need for general anaesthetic.
73 Thus, there has been interest in the development of novel, non-convulsive brain stimulation
74 techniques that are well-tolerated and have a benign side effect profile, such as transcranial
75 electrical stimulation. These neuromodulatory techniques could have the greatest potential for
76 translation into widespread clinical use, being relatively inexpensive, easy to use, portable,
77 and safe (Bikson et al., 2016; Nikolin et al., 2018). Here we report an investigation of the
78 efficacy of one such technique, transcranial random noise stimulation (tRNS), for the
79 treatment of depression.

80 Transcranial electrical stimulation involves applying a weak electrical current to
81 cerebral tissue via scalp electrodes, resulting in modulation of neuronal membrane potentials
82 and spontaneous firing rates (M. A. Nitsche et al., 2008) that can lead to long term changes in
83 cortical excitability and plasticity (Michael Nitsche and Paulus, 2001; Michael J Player et al.,
84 2014). Applying a direct current between the electrodes, referred to as transcranial direct
85 current stimulation (tDCS), has been demonstrated to have antidepressant effects in clinical
86 trials (Colleen K Loo et al., 2012; Andre R Brunoni et al., 2013a; Andre R Brunoni et al.,
87 2017). Recent meta-analyses of randomised, sham-controlled trials have found tDCS to be

88 more effective than sham stimulation, with significantly higher remission and response rates
89 as well as a greater reduction in depressive symptoms (André R. Brunoni et al., 2016; Mutz et
90 al., 2018). As depression has increasingly been conceptualised as a disorder underpinned by
91 disrupted neuroplasticity (Pittenger and Duman, 2008; Liu et al., 2017), cumulative changes
92 to synaptic functioning may underlie the therapeutic effects observed in clinical trials of
93 tDCS (Szymkowicz et al., 2016). Modifying stimulation parameters to enhance cortical
94 excitability effects may therefore present a pathway to increase treatment efficacy.

95 tRNS is a more recently developed transcranial electrical stimulation technique that
96 involves randomly fluctuating current intensities over a broad frequency spectrum (between
97 0.1 to 640 Hz). There is some evidence that tRNS has comparable, if not greater, cortical
98 excitatory effects as compared to tDCS (Moliadze et al., 2014b; Ho et al., 2015; Inukai et al.,
99 2016b). A single session of 10 minutes of 1 milliampere (mA) tRNS to the motor cortex has
100 been found to produce a greater increase in cortical excitability than tDCS, lasting up to 60
101 minutes beyond the stimulation period (Moliadze et al., 2014a; Inukai et al., 2016a), although
102 tDCS may lead to a longer period of excitation of at least 90 minutes post-stimulation
103 (Moliadze et al., 2014a). tRNS may also be applied with a direct current offset so that the
104 stimulation incorporates neuromodulatory features of tDCS, in addition to limiting
105 homeostatic responses via randomly fluctuating current intensities. Results from Ho et al.
106 (2015) suggest that tRNS with a direct current offset may be more effective in increasing
107 motor cortical excitability than the more common application of tRNS without an offset.

108 There has been a burgeoning growth in recent years of studies investigating the
109 application of tRNS to enhance sensory processing (Ghin et al., 2018; K. S. Rufener et al.,
110 2018; Contemori et al., 2019), motor performance (Abe et al., 2019; Jooss et al., 2019), and
111 cognition (Snowball et al., 2013; Popescu et al., 2016; Mammarella et al., 2017; Shalev et al.,
112 2018; Tyler et al., 2018) in healthy participants with largely promising results. To date,

113 however, few studies have examined the effectiveness of tRNS for clinical/therapeutic uses,
114 with such studies typically characterised by small sample sizes and/or varying efficacy (Chan
115 et al., 2012; Haesebaert et al., 2014; U. Palm et al., 2016; Hayward et al., 2017; Kreuzer et
116 al., 2017; Salemi et al., 2019). Regarding the effects of tRNS on mood, there is currently only
117 one report involving treatment of major depressive disorder (MDD). Chan et al. (2012)
118 reported a case of a patient diagnosed with MDD who had responded to two trials of tDCS (2
119 mA, 20 minutes, 15 sessions over 3 weeks) prior to trialling a 4-week course of open-label
120 tRNS (2 mA range with 1 mA direct current offset, 20 sessions lasting 20 minutes each). It
121 was found that by the 15th session, there was a 63% reduction from baseline in the severity of
122 depressive symptoms, compared with a reduction of 31% and 25% at the end of the acute
123 treatment phase in the two prior trials of tDCS. For all three trials, depression scores at
124 baseline were similar but the patient reported faster improvement with tRNS and lesser skin
125 sensations compared to tDCS. Given this encouraging case report finding, and the potential
126 theoretical advantages of tRNS relative to tDCS, further investigation of the antidepressant
127 effects of tRNS is warranted.

128 The primary aim of this study, therefore, was to conduct the first randomised, sham-
129 controlled trial of tRNS in depression. It was hypothesised that tRNS would have significant
130 antidepressant efficacy compared with a sham control over a 4-week treatment phase. A
131 secondary aim of this study was to examine whether antidepressant effects of tRNS were
132 mediated by restoration of brain neuroplasticity. We hypothesised that antidepressant
133 response to tRNS would be associated with increased brain plasticity, given prior findings of
134 reduced neuroplasticity in depressed individuals compared to healthy matched controls
135 (Michael J Player et al., 2013), and findings suggesting a normalisation of neuroplasticity
136 following antidepressant treatment using tDCS (Michael J Player et al., 2014). Lastly, as this
137 is the first treatment trial of tRNS for depression, a comprehensive neuropsychological test

138 battery was designed specifically to be sensitive to symptom changes, measure any adverse
139 cognitive effects, and to assess any potential acute cognitive enhancing effects.

140 **Materials and Methods**

141 **Trial design**

142 The main study phase used a double-blinded, parallel, randomized, sham-controlled
143 design. Participants were assigned by a computer-generated random number sequence to one
144 of two groups: active tRNS or sham tRNS. Randomization was stratified according to
145 whether participants were diagnosed with unipolar or bipolar depression. Participants were
146 required to attend a total of 20 tRNS sessions over four weeks conducted on consecutive
147 weekdays during the sham-controlled phase. Participants who missed five or more sessions
148 during the sham-controlled phase were withdrawn from the trial, and were excluded from
149 analyses using a per-protocol approach. All participants were offered an additional 20
150 sessions of open-label active tRNS over four weeks, also administered every weekday. After
151 treatment in the acute daily treatment phases, participants entered a taper phase during which
152 they received once weekly tRNS treatment for four weeks with the final taper session
153 coinciding with a 1-month follow-up visit. Participants were then followed up at 3, 6 and 9
154 months. Participants and raters were blinded to tRNS condition and blinding was maintained
155 until the study was completed and the dataset locked.

156 Mood, neuroplasticity, and neuropsychological function were assessed at the intervals
157 shown in Supplementary Table S1. Adequacy of blinding to treatment was assessed at the end
158 of the sham-controlled phase by asking participants and raters to guess the tRNS condition
159 administered during the first four weeks of treatment. To investigate whether treatment
160 expectations may be a predictor of response, participants completed the Treatment

161 Expectancy Questionnaire (TEQ; see Supplementary Figure S1) at baseline before the first
162 tRNS session.

163 The study was powered for the primary aim of testing efficacy over the sham-
164 controlled phase. From pilot data, it was assumed that tRNS would be at least as effective as
165 tDCS when tested in a sham-controlled trial, given that sampling criteria were very similar.
166 Means and standard deviations of the active and sham treatment groups from our previous,
167 sham-controlled, 3-week trial of tDCS (Colleen K Loo et al., 2012) were used, with
168 outcomes extrapolated for a 4-week comparison period. This resulted in an effect size of
169 Cohen's $d = 0.7$. For 80% power and $\alpha = 0.05$, a sample of 33 subjects per group was
170 required to demonstrate a difference between active and sham treatment.

171

172 Participants

173 At study entry, participants were at least 18 years old; in a current major depressive
174 episode (as part of a MDD or Bipolar Disorder) of a minimum four weeks duration, defined
175 according to Diagnostic and Statistical Manual of Mental Disorders (fourth edition, text
176 revision; DSM-IV-TR) criteria and established using the Mini International Neuropsychiatric
177 Interview (MINI; Version 5.0.0) (Sheehan et al., 1998) and study clinician assessment; and
178 had a total score of at least 20 on the Montgomery-Asberg Depression Rating Scale
179 (MADRS) (Montgomery and Asberg, 1979). Participants were free of antidepressant
180 medications, or continued on stable doses of antidepressant medications to which they had
181 failed to respond after an adequate course of treatment, with dosage unchanged for at least
182 four weeks prior to study entry. Bipolar participants were required to be on a mood stabilizer
183 medication (e.g. lithium, valproate, or carbamazepine) as prophylaxis against treatment-
184 emergent mania or hypomania for the duration of the study.

185 Exclusion criteria included: psychotic disorder as per DSM-IV-TR; drug or alcohol
186 abuse or dependence within 12 months of study entry; inadequate response to ECT in the
187 current depressive episode; current benzodiazepine medication; rapid clinical response
188 required (e.g., due to high suicide risk); clinically defined neurological disorder or insult;
189 metal in the cranium; skull defects; skin lesions on the scalp at electrode sites; or pregnancy.

190 The study was approved by the human research ethics committee of the University of
191 New South Wales and was conducted at the Black Dog Institute in Sydney, Australia.
192 Participants provided written informed consent for this study. Recruitment began in January
193 2013 and the last follow-up was conducted in 2017. The study was registered with the
194 ClinicalTrials.gov website (Identifier: NCT01792414).

195

196 [Transcranial random noise stimulation](#)

197 A DC-Stimulator Plus device (NeuroConn GmbH, Germany) applied high frequency
198 tRNS (100-640 Hz) via two 7 x 5 cm saline-soaked sponge-covered electrodes held in
199 position by a headband. Active tRNS was administered for 30 mins per session with a range
200 of 2 mA and an offset of 2 mA. The anode was placed over F3 (as per the 10-20 international
201 electroencephalogram system), corresponding to the left dorsolateral prefrontal cortex
202 (LDLPFC), and the cathode over F8. For sham stimulation, the current was ramped up over
203 10 s, left on for 30 s, then gradually ramped down over 10 s, so that both treatment groups
204 experienced an initial tingling sensation. The tRNS machine was then left on until the end of
205 the session to preserve blinding. This sham procedure resulted in adequate blinding for tDCS
206 in previous trials (e.g., (C. K. Loo et al., 2010; Colleen K Loo et al., 2012)), and was
207 therefore expected to be sufficient for tRNS, which produces milder skin sensations
208 compared to tDCS (Ambrus et al., 2010). Participants were comfortably seated at rest and did
209 not engage in any particular tasks during stimulation.

210

211 Clinical outcome measures

212 The primary outcome measure for comparing active and sham tRNS was the MADRS,
213 which was administered by trained raters with established inter-rater reliability (intraclass
214 correlation coefficient > 0.7). Secondary measures were the Clinician Global Impression –
215 Improvement (CGI-I) (Guy, 1976), Beck Depression Inventory (BDI-II) (Beck et al., 1996) and
216 Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form (Q-LES-SF)
217 (Endicott et al., 1993) scales.

218

219 Neuroplasticity outcome measures

220 As an optional study offered to participants in the main tRNS trial, a paired
221 associative stimulation (PAS) paradigm previously described in M. J. Player et al. (2012) was
222 used to assess the effects of tRNS on neuroplasticity. The PAS testing was conducted at
223 baseline before the first tRNS session, and again after completion of the sham-controlled and
224 open-label phases. Briefly, the PAS paradigm involves measuring motor evoked potentials
225 (MEPs) following single-pulse transcranial magnetic stimulation (TMS) via
226 electromyography (EMG) before and after applying a stimulation protocol (i.e., PAS) to the
227 motor cortex to assess changes in motor cortical excitability (see the Supplementary Material
228 for a detailed description of PAS methodology).

229

230 Neuropsychological outcome measures

231 The following neuropsychological battery was administered to comprehensively
232 assess cognitive function: California Verbal Learning Test-II (CVLT-II) (Delis et al., 2000) –
233 verbal learning and memory; Ruff 2 & 7 (Ruff and Allen, 1996) – attention processes;
234 Wechsler Adult Intelligence Scale-IV edition (WAIS-IV) Digit Span subtest (Wechsler,

235 2008) – simple auditory attention and working memory; Symbol Digit Modality Test
236 (SDMT) (Smith, 1991) – psychomotor processing speed; Delis-Kaplan Executive Function
237 System (D-KEFS) Verbal Fluency test (Delis et al., 2001) – phonemic fluency, semantic
238 fluency, cognitive flexibility; and Cognitive Failures Questionnaire (Broadbent et al., 1982) –
239 subjective cognitive functioning. Alternative versions of the CVLT-II, D-KEFS Verbal
240 Fluency, and SDMT were used to minimize practice effects. In addition, computer
241 administered cognitive tests were used to assess safety and acute effects. A simple reaction
242 time test, in which participants were instructed to press a space bar as soon as they saw a
243 cross appear in the middle of a computer screen, was administered immediately before and
244 after the first tRNS session. An Emotion Recognition Task (Montagne et al., 2007), which
245 assessed recognition of six basic facial emotions, was also administered after the first tRNS
246 session.

247

248 Physical adverse events

249 As an additional safety outcome measure, physical adverse events were assessed each
250 session using a tRNS Side Effects Questionnaire (Supplementary Figure S2), adapted from
251 Andre Russowsky Brunoni et al. (2011), which collected information regarding the type of
252 adverse event, its severity, and its causality.

253

254 Statistical Analyses

255 All statistical analyses were conducted using SPSS software (IBM SPSS Statistics 25
256 for Windows; SPSS Inc.). Outcome measures were analysed for change over the sham-
257 controlled phase using a mixed-effects repeated measures (MERM) model with a restricted
258 number of covariates. Time was entered as a repeated measures factor with an unstructured
259 covariance matrix, tRNS Condition (active or sham) was a between-subjects factor, and

260 subjects were included as a random effect. For mood and quality of life outcomes, covariates
261 were selected based on prior reports of their significant effect on antidepressant response to
262 transcranial electrical stimulation; these included treatment resistance (Bikson et al., 2016)
263 (assessed by the Maudsley Staging Method (Fekadu et al., 2009)), and presence of concurrent
264 antidepressant medications e.g. selective-serotonin reuptake inhibitors, serotonin–
265 norepinephrine reuptake inhibitors (A. R. Brunoni et al., 2013b; Andre R Brunoni et al.,
266 2013a). A MERM model was similarly used for neuropsychological outcomes, with MADRS
267 mood scores at the respective time points included as a covariate. Acute cognitive effects
268 following the first session were examined using a two-way repeated measure analysis of
269 variance (RMANOVA), with factors of tRNS Condition and Time (pre and post session 1).
270 For the Emotion Recognition Task, a multivariate ANOVA (MANOVA) was conducted with
271 the between-subject factor of tRNS Condition.

272 Additional MERM analyses were conducted for the primary outcome measure
273 (MADRS). Baseline scores on the TEQ were added as a covariate to the MERM analysis to
274 test whether treatment expectations modified mood outcomes. To assess whether medication
275 use affected outcomes, each medication class (antidepressants, benzodiazepines,
276 antipsychotics, lithium and anticonvulsants) was entered as the only covariate in separate
277 MERM analyses.

278 The number of responders (defined as a reduction in MADRS total score of $\geq 50\%$
279 from baseline) and remitters (defined as a final MADRS total score < 10) at the end of the
280 sham-controlled phase were compared between active and sham tRNS groups using a
281 Fisher's exact test.

282 The association between participant or rater guesses (active or sham) and the
283 participant's assigned tRNS condition (active or sham) was tested using a Pearson Chi-square

284 test with Yates' continuity correction. Cohen's kappa statistic was used to assess agreement
285 between participant and rater guesses.

286 Statistical tests were two-tailed and significance was set at $p < 0.05$.

287 **Results**

288 A total of 69 participants met inclusion criteria and were randomized to receive either active
289 or sham tRNS during the sham-controlled phase (see the CONSORT flow diagram,
290 Supplementary Figure S3). A total of 66 participants (sham: 34, active: 32) completed the
291 sham-controlled phase and were analysed using a per-protocol approach. Table 1 shows
292 demographic and clinical characteristics for active and sham tRNS groups at baseline.

293 **Table 1. Comparison of demographic and clinical characteristics at baseline.**

	Sham	Active
n	34	32
<i>Medications (yes/no)</i>		
Any concurrent medication	27/7	22/10
Antidepressant	23/11	20/12
Lithium	1/33	2/30
Benzodiazepine*	2/32	2/30
Antipsychotic	6/28	4/28
Anticonvulsant	5/29	1/31
<i>Clinical and demographic variables (m, SD)</i>		
Gender (m/f)	19/15	17/15
Melancholic (yes/no)	19/9	12/12
MDD/BP1/BP2	30/3/1	30/0/2
Age (years)	48.8 (12.3)	47.5 (12.0)
Age at onset (years)	27.0 (9.6)	27.5 (9.6)
Duration of current episode (months)	24.4 (32.2)	37.2 (48.0)
Duration of previous episodes (months)	65.9 (65.8)	88.5 (93.6)
Antidepressants failed current episode	2.1 (1.7)	2.6 (2.9)
Total lifetime failed antidepressants	4.0 (3.0)	5.0 (5.1)
Maudsley Staging score	7.3 (2.1)	6.5 (1.9)
Baseline MADRS score	29.5 (4.6)	30.1 (5.0)
Baseline BDI-II score	33.8 (9.1)	34.1 (9.4)
Baseline CGI-S score	4.4 (0.6)	4.4 (0.6)
Baseline Q-LES-SF score	32.8 (10.5)	34.9 (11.2)
Baseline TEQ score	24.5 (7.6)	24.1 (7.1)

294 *Participants were required to cease benzodiazepine medication use prior to commencing the trial.

295 MDD: Major depressive disorder. BP1/BP2: Bipolar I and bipolar II disorder. MADRS: Montgomery-Asberg Depression
 296 Rating Scale. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. BDI-II: Beck Depression
 297 Inventory. CGI-S: Clinician Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7-
 298 extremely ill. TEQ: Treatment Expectancy Questionnaire.


299

300 Clinical outcome measures

301 Table 2 shows the results for all MERM analyses of mood and quality of life outcome
 302 measures during the sham-controlled phase using per-protocol and intention-to-treat
 303 approaches in accordance with CONSORT guidelines for parallel group randomised control
 304 trials (Schulz et al., 2010). MERM analysis of MADRS scores showed a significant effect of
 305 Time ($p < 0.001$). There was, however, no effect of tRNS Condition ($p = 0.630$), and no
 306 significant Time \times Condition interaction ($p = 0.445$; see Figure 1). Repeating the analysis

307 while incorporating scores from the Treatment Expectations Questionnaire as an additional
308 covariate did not modify outcomes. Concurrent medications did not significantly affect
309 outcomes when entered as covariates in separate MERM analyses (see Supplementary Table
310 S2). Supplementary Table S3 shows results from MERM analyses of all outcome measures
311 acquired during the acute daily treatment phases combined (i.e. both sham-controlled and
312 open-label phases). Supplementary Figure S4 shows graphs of mood and quality of life
313 measures for all time-points up to the 9-month follow-up assessment.

314 One participant in the active tRNS group (3.1%), and five participants receiving sham
315 tRNS (14.7%), were considered treatment responders after completion of the sham-controlled
316 phase (i.e. following 20 sessions of tRNS). Only two participants met the remission criterion,
317 both in the sham tRNS condition (5.9%). Fisher's exact tests revealed no statistically
318 significant differences between active and sham tRNS conditions for response ($p = 0.198$)
319 and remission ($p = 0.493$) rates.



320
321 **Figure 1. Mood scores.** Graph showing MADRS scores (estimated marginal means \pm
322 SD) across rating time points, including the sham-controlled phase (from baseline to 4-
323 weeks), open-label phase (from 4 – 8 weeks), and 1-month follow-up assessment following

324 the final taper session. Dotted lines indicate sham tRNS sessions delivered during the sham-
325 controlled phase.

326 **Table 2. Mood and quality of life outcome measures.** Estimated marginal means and results from MERM analyses during the sham-
 327 controlled phase. MERM analyses were performed including the following covariates: Maudsley staging method total score as a measure of
 328 treatment resistance, and antidepressant use. Statistically significant p-values (<0.05) are highlighted in bold.

<i>Mood Assessments - mean (n, SEM)</i>	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	Sham	Active	F	p	F	p	F	p
Per-protocol analysis												
MADRS	29.1 (33, 0.8)	28.9 (32, 0.8)	24.4 (33, 1.0)	24.8 (32, 1.1)	22.1 (34, 1.2)	23.7 (32, 1.3)	0.24	0.630	41.73	<0.001	0.82	0.445
BDI-II	32.6 (31, 1.7)	33.2 (28, 1.8)	25.2 (34, 1.9)	27.2 (32, 2.0)	22.1 (32, 1.9)	24.9 (31, 2.0)	0.72	0.399	24.56	<0.001	0.46	0.762
CGI-I	-	-	3.5 (33, 0.1)	3.6 (32, 0.1)	3.1 (33, 0.1)	3.4 (32, 0.1)	2.24	0.140	12.69	<0.001	2.10	0.153
Q-LES-SF	32.4 (34, 1.9)	36.0 (30, 2.1)	-	-	43.5 (32, 2.8)	43.9 (31, 2.9)	0.45	0.503	31.67	<0.001	0.84	0.362
Intention-to-treat analysis												
MADRS	29.1 (34, 0.8)	29.0 (34, 0.8)	24.4 (33, 1.0)	24.8 (34, 1.1)	22.1 (34, 1.2)	23.7 (32, 1.3)	0.29	0.593	43.09	<0.001	0.77	0.467
BDI-II	32.4 (32, 1.6)	33.4 (30, 1.7)	24.9 (34, 1.9)	27.1 (34, 2.0)	21.9 (32, 1.9)	25.1 (31, 2.0)	1.07	0.306	25.07	<0.001	0.58	0.678
CGI-I	-	-	3.5 (33, 0.1)	3.6 (34, 0.1)	3.1 (33, 0.1)	3.4 (32, 0.1)	2.60	0.112	13.07	<0.001	1.98	0.165
Q-LES-SF	32.5 (35, 1.8)	35.8 (32, 2.0)	-	-	43.6 (32, 2.8)	43.8 (31, 2.9)	0.37	0.545	32.00	<0.001	0.80	0.376

329 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global Impression Improvement scale, is a 7-point clinician-rated scale ranked
 330 from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. m: Mean. SEM: Standard error of measure.

331 Neuroplasticity outcome measures

332 A total of 44 participants (sham: 25, active: 19) completed the optional PAS study to
333 assess changes in motor cortical excitability. A MERM analysis found no significant effects
334 of Time ($p = 0.209$) or Condition ($p = 0.780$), and no significant Time \times Condition interaction
335 ($p = 0.570$; see Table 3, and Supplementary Figure S5). Furthermore, change in MADRS
336 scores did not correlate with changes in MEP amplitudes from baseline to the end of the
337 sham-controlled phase ($r = -0.02$, $p = 0.905$; Supplementary Figure S6). Results from
338 intention-to-treat analyses are also reported in Supplementary Table S4.

339

340 Neuropsychological outcomes

341 Neuropsychological outcomes during the sham-controlled phase are shown in Table 3. There
342 were no significant main effects of Time, and no significant Time \times Condition interaction
343 effects for all neuropsychological measures. Results from intention-to-treat analyses are also
344 reported in Supplementary Table S4.

345 **Table 3. Neuroplasticity and neuropsychological outcome measures.** Estimated marginal means and results from MERM analyses
 346 during the sham-controlled phase. The neuroplasticity MERM analysis were performed including the following covariates: Maudsley staging
 347 parameters total score as a measure of treatment resistance, and antidepressant use. Neuropsychological MERM analyses were performed using
 348 MADRS scores as a covariate. Statistically significant p-values (<0.05) are highlighted in bold.

	Baseline		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	F	p	F	p	F	p
<i>Neuroplasticity Assessment (m, SEM)</i>										
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	1.31 (0.09)	1.40 (0.10)	0.08	0.780	1.63	0.209	0.33	0.570
<i>Neuropsychological Assessments (m, SEM)</i>										
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.8)	48.7 (2.2)	46.3 (2.3)	49.7 (2.2)	2.12	0.148	0.12	0.734	0.01	0.913
CVLT-II: Long delay free recall z-score	-0.41 (0.21)	0.03 (0.22)	-0.64 (0.22)	-0.38 (0.21)	2.69	0.104	1.85	0.176	0.20	0.653
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.5 (0.7)	10.9 (0.7)	11.9 (0.7)	0.97	0.327	0.01	0.945	0.32	0.575
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	9.8 (0.8)	11.8 (0.8)	2.84	0.094	0.05	0.828	0.80	0.372
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.1 (0.6)	9.6 (0.6)	10.6 (0.6)	3.36	0.069	0.50	0.480	0.02	0.888
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	49.9 (1.9)	51.3 (1.9)	53.6 (1.8)	1.66	0.200	3.45	0.066	0.01	0.946
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.6 (2.4)	50.4 (2.4)	48.7 (2.3)	1.02	0.316	0.34	0.561	0.08	0.779
SDMT: Total correct z-score	-0.31 (0.18)	0.25 (0.18)	-0.02 (0.19)	0.41 (0.18)	7.78	0.006	1.32	0.254	0.15	0.703
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.6)	10.5 (0.6)	12.6 (0.5)	13.00	<0.001	2.57	0.112	0.12	0.732
CFQ: Total score	50.0 (2.2)	46.8 (2.3)	49.9 (2.3)	50.0 (2.2)	0.52	0.474	0.40	0.528	0.57	0.451

349 PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test.
 350 D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measure.

351 Acute cognitive effects

352 For reaction time, the main effects of Time ($p = 0.404$), Condition ($p = 0.992$), and the Time
353 \times Condition interaction effect ($p = 0.949$) were not statistically significant. Further, for the
354 Emotion Recognition Task the main effect of tRNS Condition was not statistically significant
355 ($p = 0.347$).

356 Physical adverse events

357 Adverse events occurring during the sham-controlled and open-label phases of the
358 trial are presented in Table 4. Side-effects were transient and mild-to-moderate in severity.
359 Pearson Chi-square tests revealed significantly more instances of erythema (skin redness; $p <$
360 0.001), paraesthesia (tingling, burning, and itching sensations; $p < 0.001$), fatigue ($p = 0.006$),
361 and dizziness/light-headedness ($p = 0.002$) following active tRNS as compared to sham tRNS
362 sessions.

363 **Table 4. Physical adverse event frequency.** Adverse events are sorted according to
 364 overall likelihood of occurrence, with events most likely to occur listed first. Differences in
 365 frequency of adverse event occurrence during the sham-controlled phase was tested using
 366 Pearson Chi-square tests with Yates' continuity correction. Statistically significant p-values
 367 (<0.05) are highlighted in bold.

	Sham-controlled phase						Open-label phase	
	Sham (646 sessions)		Active (650 sessions)		Pearson Chi-square		Active (1161 sessions)	
	n	%	n	%	χ^2	p-value	n	%
Erythema	129	20.0	454	69.8	323.67	<0.001	781	67.3
Tingling	126	19.5	332	51.1	139.96	<0.001	623	53.7
Burning	15	2.3	251	38.6	214.14	<0.001	370	31.9
Itching	40	6.2	97	14.9	25.21	<0.001	170	14.6
Fatigue	33	5.1	60	9.2	7.66	0.006	75	6.5
Headache	43	6.7	30	4.6	2.17	0.141	31	2.7
Dizziness/light-headedness	10	1.5	31	4.8	9.95	0.002	48	4.1
Nausea	7	1.1	15	2.3	2.22	0.136	36	3.1
Scalp Discomfort	7	1.1	9	1.4	0.06	0.811	10	0.9
Other	14	2.2	26	4.0	3.05	0.081	58	5.0

368

369 **Blinding integrity**

370 Participants were asked to guess their treatment condition at the end of the double-
 371 blinded sham-controlled phase. 75% of participants in the sham condition correctly guessed
 372 they received sham tRNS, and 55% of participants in the active condition correctly guessed
 373 they had received active tRNS. A Pearson Chi-square test of participant guesses was
 374 significant ($\chi^2 = 4.68$; $p = 0.031$), suggesting that participants were not adequately blinded to
 375 their treatment condition. To determine whether participant guesses of treatment condition
 376 may have influenced mood outcomes, we performed a post-hoc simple linear regression
 377 analysis; percent change in MADRS score over the 4-week sham-controlled phase was
 378 selected as the dependent variable, and participant guess (active, sham) as the independent
 379 variable. This analysis was not statistically significant ($R^2 = 0.023$, $F = 1.43$, $p = 0.237$).

380 Blinded study raters were similarly asked to guess participants' treatment condition at
381 the end of the sham-controlled phase. Raters correctly guessed that participants had received
382 sham tRNS 56% of the time, and active tRNS 31% of the time. A Pearson Chi-square test
383 found this difference not to be statistically significant ($\chi^2 = 0.492$; $p = 0.483$). Furthermore,
384 Cohen's kappa showed no agreement between participant and rater guesses ($\kappa = 0.134$; $p =$
385 0.329).

386 Discussion

387 Here we report the results of the first randomized control trial to examine the efficacy
388 of tRNS for the treatment of depression. Although there was a significant reduction of
389 depressive symptoms over the duration of the study period, there was no difference in the rate
390 of improvement between sham and active tRNS conditions. Further, there was no significant
391 effect of tRNS on neuroplasticity measures in the subset of participants that completed the
392 PAS paradigm, suggesting that stimulation did not increase global cortical excitability. tRNS
393 was found to be safe with no adverse acute cognitive, neuropsychological or severe physical
394 side effects. However, tRNS resulted in a higher incidence rate of skin redness (erythema)
395 and paraesthesia (tingling, itching, and burning sensations) in the active condition, as well as
396 fatigue and dizziness/light-headedness, which occurred in fewer than 10% of sessions.
397 Nevertheless, the stimulation protocol was well-tolerated with only one participant dropping-
398 out due to adverse effects, which were not conclusively associated with tRNS.

399 The results of this study do not support the use of tRNS with the current stimulation
400 parameters as a therapeutic intervention for the treatment of depression. Despite encouraging
401 initial evidence of significant reductions in depression scores in patients with fibromyalgia
402 (Curatolo et al., 2017), and a case report of improvement in MDD (Chan et al., 2012), mood
403 and quality of life outcomes in the active tRNS group were no different from the placebo-
404 controlled response in the sham group at all time-points. The size of reductions in depressive
405 symptoms observed in both conditions of the present study is broadly similar to the sham
406 condition of previous trials of tDCS for depression (Blumberger et al., 2012; Colleen K Loo
407 et al., 2012; U Palm et al., 2012; Andre R Brunoni et al., 2013a; Bennabi et al., 2015;
408 Sampaio-Junior et al., 2018). Of these previous tDCS trials, our study design was most
409 similar to a recent international multisite investigation conducted by our group, which
410 observed improvements in depression scores of 27.8% and 22.3% in sham and active tDCS

411 conditions, respectively, as compared to 24.1% and 18.0% in sham and active tRNS
412 conditions (Colleen K Loo et al., 2018). We recruited participants using analogous
413 inclusion/exclusion criteria, participant demographic and clinical characteristics, and adopted
414 comparable stimulation parameters, at least in terms of treatment duration (30 minutes),
415 session number and frequency (20 daily weekday sessions), and direct current intensity (2
416 mA direct current offset in the present study vs a marginally stronger current intensity of 2.5
417 mA in the tDCS study). Interestingly, the present tRNS trial and Colleen K Loo et al. (2018)
418 have used the highest total number of sessions and strongest stimulation parameters,
419 including current intensity, compared to other investigations of the antidepressant effects of
420 transcranial electrical stimulation (Blumberger et al., 2012; Colleen K Loo et al., 2012; U
421 Palm et al., 2012; Andre R Brunoni et al., 2013a; Bennabi et al., 2015), with both studies
422 reporting no advantage of active stimulation over sham. Overall, studies show tDCS has
423 antidepressant efficacy (Mutz et al., 2018), though one study suggested this may be less than
424 escitalopram (Andre R Brunoni et al., 2017).

425 Another possible explanation for null findings in the present study is that the sample
426 was too severely ill to respond to tRNS treatment. On average, participants had failed 4-5
427 antidepressants and depression scores just below the cut-off for severe depression (MADRS
428 > 34; see Table 1). Research suggests that participants with treatment resistant depression do
429 not respond as well transcranial electrical stimulation, such as tDCS (Blumberger et al., 2012;
430 U Palm et al., 2012; Bennabi et al., 2015).

431 The synaptic plasticity hypothesis of depression purports that MDD is characterized
432 by a partial reduction in long-term potentiation-like processes (Michael J Player et al., 2013;
433 Kuhn et al., 2016), suggesting that impaired synaptic plasticity, particularly in the prefrontal
434 cortex, is a key feature of the pathophysiology of depression (Goto et al., 2010; Duman et al.,
435 2016; Noda et al., 2018). This hypothesis is supported by evidence that the therapeutic

436 efficacy of antidepressants is, at least partly, due to their capacity to increase neural plasticity
437 (Santarelli et al., 2003; Castrén and Hen, 2013). Similarly, prior work from our group has
438 demonstrated that a course of tDCS increases neuroplasticity and mood outcomes in
439 depression. However, a correlation between these measures could not be confirmed due to the
440 limited sample size ($n = 18$) (Michael J Player et al., 2014). Despite a larger sample size from
441 which to detect small effects of the intervention, we did not see an increase in neuroplasticity
442 levels following tRNS. Previous research has shown that tRNS can induce acute neuroplastic
443 after-effects, measured by investigating changes to motor cortex excitability using TMS
444 motor evoked potentials (Terney et al., 2008; Chaieb et al., 2015; Ho et al., 2015). However,
445 there is no evidence to date to suggest cumulative changes in neuroplasticity following a
446 course of multiple repeated sessions of tRNS, as assessed in this study. An important caveat
447 to our results is that only a subset of participants (44/69) completed the PAS study. It is
448 theoretically possible that the subset of participants who underwent the PAS protocol had
449 different clinical, physiological, or behavioural characteristics (e.g. greater levels of
450 motivation) and may thus not be representative of the larger sample.

451 The exact purported mechanisms of action for prolonged cortical excitation following
452 tRNS are unclear, but may include either 1) temporal summation of neural activity when
453 random noise stimuli and ongoing endogenous neuronal activity occur in close succession
454 (Fertonani et al., 2011), and/or 2) enhancement of neuronal signalling via the principle of
455 stochastic resonance (van der Groen and Wenderoth, 2017). The latter refers to signals that
456 are too weak to exceed a threshold being amplified by adding a random noise stimulus,
457 improving the signal-to-noise ratio and the synchronization and coherence of neuronal
458 networks (Moss et al., 2004; Pavan et al., 2019). Though more research is required to
459 determine which of these mechanisms dominates, the action of tRNS appears to rely heavily
460 on detection and propagation of weak ongoing endogenous neuronal signals. The notion of

461 stochastic resonance has been demonstrated in several tRNS experiments aimed at enhancing
462 sensitivity to sensory inputs, including visual, auditory, and tactile stimuli (van der Groen and
463 Wenderoth, 2017). Interestingly, investigations of auditory (Katharina S Rufener et al., 2017)
464 and visual (Van der Groen et al., 2018) perceptual thresholds have shown that tRNS has its
465 largest effect on near-threshold stimuli, whereas stimuli clearly above and below threshold
466 were unaffected. It may be for this reason that the only positive randomized control trials
467 using tRNS in clinical populations have stimulated the sensory and motor cortices,
468 specifically in the treatment of tinnitus via the auditory cortex (Vanneste et al., 2013), or
469 stimulation of the motor cortex for chronic pain in fibromyalgia (Curatolo et al., 2017). tRNS
470 may restore the dysfunctional activity in these cortical structures by normalizing their
471 capacity to filter weak signals amidst background neural noise. In complex disorders such as
472 depression, however, it is unclear what the depressed ‘signal’ might be. Studies seeking to
473 use tRNS for other complex disorders by stimulating prefrontal cortical regions have also
474 reported negative findings, i.e. for the treatment of multiple sclerosis (U. Palm et al., 2016),
475 and vegetative state (Mancuso et al., 2017). Similarly to depression, these illnesses do not
476 consist of a well-defined neural signal whose signalling properties can be augmented by
477 tRNS to revert pathophysiological dysfunctions of brain activity.

478 Although the present study reports null findings for the use of tRNS in depression, it
479 provides valuable information regarding the safety and tolerability of multiple repeated
480 sessions of tRNS. To the best of our knowledge, the previous longest delivery of tRNS was
481 15 sessions (Chan et al., 2012), whereas participants in the current study experienced up to 40
482 sessions over eight weeks if allocated to the active tRNS condition. Adverse events of
483 erythema and paraesthesia were reported more frequently in the active tRNS condition as
484 compared to sham. These results are comparable to those observed in the tDCS literature, in
485 which meta-analyses similarly suggest a greater frequency of erythema and paraesthesia

486 (Moffa et al., 2017; Nikolin et al., 2018). Of interest, fatigue and dizziness/light-headedness
487 were also noted more frequently during active tRNS sessions. These side effects are not a
488 common adverse effect of tDCS and might be unique to the tRNS stimulation parameters
489 used in the current study, for example, due to the current intensity ranging as high as 3 mA (2
490 mA direct offset with ± 1 mA amplitude fluctuation). Importantly, fatigue and dizziness/light-
491 headedness occurred rarely, in only 9.2% of sessions for fatigue, and 4.8% for light-
492 headedness. Additionally, these adverse events were transient, resolved on their own shortly
493 after cessation of stimulation, and were not reported to be severe in intensity.

494 A limitation of the present study is that blinding was not preserved, possibly due to
495 the increased incidence of adverse events during active tRNS compared to sham. One would
496 expect inadequate blinding to reduce placebo effects for participants in the sham condition,
497 and potentially enhance them for participants receiving active tRNS, thereby increasing the
498 likelihood of observing a difference between groups. This was not the case in the present
499 study. Indeed, scores for mood outcomes were quantitatively (but not significantly) better in
500 the sham condition compared to active tRNS, suggesting that inadequate blinding did not bias
501 results in favour of the active treatment. Future studies may consider alternative methods to
502 adequately blind participants, including the use of a topical salve beneath the site of
503 stimulation to reduce paraesthetic effects and erythema (McFadden et al., 2011; Guarienti et
504 al., 2015), or comparisons against an active control condition (Fonteneau et al., 2019).

505 A major strength of the present study is the research design, which included double
506 blinding of participants and raters, examination of mood outcomes in addition to
507 neuroplasticity changes, comprehensive assessment of adverse events using
508 neuropsychological and physical measures, reporting of long-term follow-up outcomes up to
509 9-months following completion of the open-label phase, and rigorous statistical analysis
510 methodology informed by CONSORT guidelines.

511 **Conclusion**

512 This study represents the first randomised control trial for the use of tRNS to treat
513 depression. Our findings do not lend support for the use of tRNS as a therapeutic intervention
514 for depression. Antidepressant response was similar between active and sham tRNS
515 conditions. tRNS did not increase motor cortical excitability, a measure of neuroplasticity
516 associated with antidepressant response in other successful therapeutic clinical trials of
517 depression (Santarelli et al., 2003; Castrén and Hen, 2013). The profile of adverse events for
518 tRNS was similar to that of tDCS, with a significantly greater likelihood of erythema and
519 paraesthesia in the active tRNS condition, in addition to a higher incidence rate of fatigue and
520 dizziness/light-headedness. Participant blinding was not preserved and may be related to the
521 increased frequency of side effects in the active condition. Overall, the treatment was well-
522 tolerated by participants.

523

524 **Funding**

525 This study was funded by a National Health and Medical Research Council
526 (NHMRC) Project Grant: APP1051423.

527

528 **Conflict of Interest**

529 CL has served on a Janssen Advisory Board for Janssen and received an honorarium
530 from Mecta for teaching at an international electroconvulsive therapy (ECT) course. The
531 remaining authors have no conflicts of interest to declare.

532

533 **References**

- 534 Abe T, Miyaguchi S, Otsuru N, Onishi H (2019) The effect of transcranial random noise stimulation on
535 corticospinal excitability and motor performance. *Neurosci Lett* 705:138-142.
- 536 Ambrus GG, Paulus W, Antal A (2010) Cutaneous perception thresholds of electrical stimulation
537 methods: comparison of tDCS and tRNS. *Clin Neurophysiol* 121:1908-1914.
- 538 Beck AT, Steer RA, Brown GK (1996) *Manual for Beck Depression Inventory-II*. San Antonio, TX: The
539 Psychological Corporation.
- 540 Bennabi D, Nicolier M, Monnin J, Tio G, Pazart L, Vandell P, Haffen E (2015) Pilot study of feasibility of
541 the effect of treatment with tDCS in patients suffering from treatment-resistant depression treated
542 with escitalopram. *Clin Neurophysiol* 126:1185-1189.
- 543 Bikson M et al. (2016) Safety of Transcranial Direct Current Stimulation: Evidence Based Update
544 2016. *Brain Stimul* 9:641-661.
- 545 Blumberger D, Tran L, Fitzgerald P, Hoy KB, Daskalakis ZJ (2012) A randomized double-blind sham-
546 controlled study of transcranial direct current stimulation for treatment-resistant major depression.
547 *Front Psychiatry* 3:74.
- 548 Broadbent DE, Cooper PF, FitzGerald P, Parkes KR (1982) The Cognitive Failures Questionnaire (CFQ)
549 and its correlates. *Br J Clin Psychol* 21:1-16.
- 550 Brunoni AR, Amadera J, Berbel B, Volz MS, Rizzerio BG, Fregni F (2011) A systematic review on
551 reporting and assessment of adverse effects associated with transcranial direct current stimulation.
552 *Int J Neuropsychopharmacol* 14:1133-1145.
- 553 Brunoni AR, Valiengo L, Baccaro A, Zanao TA, de Oliveira JF, Goulart A, Boggio PS, Lotufo PA,
554 Bensenor IM, Fregni F (2013a) The sertraline vs electrical current therapy for treating depression
555 clinical study: results from a factorial, randomized, controlled trial. *JAMA Psychiatry* 70:383-391.
- 556 Brunoni AR, Ferrucci R, Bortolomasi M, Scelzo E, Boggio PS, Fregni F, Dell'Osso B, Giacomuzzi M,
557 Altamura AC, Priori A (2013b) Interactions between transcranial direct current stimulation (tDCS)
558 and pharmacological interventions in the Major Depressive Episode: findings from a naturalistic
559 study. *Eur Psychiatry* 28:356-361.
- 560 Brunoni AR, Moffa AH, Sampaio-Junior B, Borriero L, Moreno ML, Fernandes RA, Veronezi BP,
561 Nogueira BS, Aparicio LV, Razza LB (2017) Trial of electrical direct-current therapy versus
562 escitalopram for depression. *N Engl J Med* 376:2523-2533.
- 563 Brunoni AR, Moffa AH, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,
564 Haffen E, Alonzo A, Loo CK (2016) Transcranial direct current stimulation for acute major depressive
565 episodes: meta-analysis of individual patient data. *Br J Psychiatry* 208:522-531.
- 566 Castrén E, Hen R (2013) Neuronal plasticity and antidepressant actions. *Trends Neurosci* 36:259-267.
- 567 Chaieb L, Antal A, Paulus W (2015) Transcranial random noise stimulation-induced plasticity is
568 NMDA-receptor independent but sodium-channel blocker and benzodiazepines sensitive. *Front*
569 *Neurosci* 9:125-125.
- 570 Chan HN, Alonzo A, Martin DM, Player M, Mitchell PB, Sachdev P, Loo CK (2012) Treatment of major
571 depressive disorder by transcranial random noise stimulation: case report of a novel treatment. *Biol*
572 *Psychiatry* 72:e9-e10.
- 573 Contemori G, Trotter Y, Cottureau BR, Maniglia M (2019) tRNS boosts perceptual learning in
574 peripheral vision. *Neuropsychologia* 125:129-136.
- 575 Curatolo M, La GB, Cosentino G, Baschi R, Salemi G, Talotta R, Romano M, Triolo G, De MT, Fierro B
576 (2017) Motor cortex tRNS improves pain, affective and cognitive impairment in patients with
577 fibromyalgia: preliminary results of a randomised sham-controlled trial. *Clin Exp Rheumatol* 35:100-
578 105.
- 579 Delis DC, Kaplan E, Kramer JH (2001) *Delis-Kaplan Executive Function System (D-KEFS)*. San Antonio,
580 TX: The Psychological Corporation.
- 581 Delis DC, Kramer JH, Kaplan E, Ober BA (2000) *California Verbal Learning Test (2nd ed.)*. San Antonio,
582 TX: The Psychological Corporation.

583 Duman RS, Aghajanian GK, Sanacora G, Krystal JH (2016) Synaptic plasticity and depression: new
584 insights from stress and rapid-acting antidepressants. *Nat Med* 22:238.

585 Endicott J, Nee J, Harrison W, Blumenthal R (1993) Quality of Life Enjoyment and Satisfaction
586 Questionnaire: a new measure. *Psychopharmacol Bull* 29:321-326.

587 Fekadu A, Wooderson S, Donaldson C, Markopoulou K, Masterson B, Poon L, Cleare AJ (2009) A
588 multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method.
589 *J Clin Psychiatry* 70:177-184.

590 Fertonani A, Pirulli C, Miniussi C (2011) Random noise stimulation improves neuroplasticity in
591 perceptual learning. *J Neurosci* 31:15416-15423.

592 Fonteneau C, Mondino M, Arns M, Baeken C, Bikson M, Brunoni AR, Burke MJ, Neuvonen T, Padberg
593 F, Pascual-Leone A (2019) Sham tDCS: A hidden source of variability? Reflections for further blinded,
594 controlled trials. *Brain Stimul*.

595 Ghin F, Pavan A, Contillo A, Mather G (2018) The effects of high-frequency transcranial random noise
596 stimulation (hf-tRNS) on global motion processing: An equivalent noise approach. *Brain Stimul*
597 11:1263-1275.

598 Goto Y, Yang CR, Otani S (2010) Functional and dysfunctional synaptic plasticity in prefrontal cortex:
599 roles in psychiatric disorders. *Biol Psychiatry* 67:199-207.

600 Guarienti F, Caumo W, Shiozawa P, Cordeiro Q, Boggio PS, Benseñor IM, Lotufo PA, Bikson M,
601 Brunoni AR (2015) Reducing transcranial direct current stimulation-induced erythema with skin
602 pretreatment: considerations for sham-controlled clinical trials. *Neuromodulation* 18:261-265.

603 Guy W (1976) ECDEU Assessment Manual for Psychopharmacology. Rockville, MD.: U.S. Department
604 of Health, Education, and Welfare.

605 Haesebaert F, Mondino M, Saoud M, Poulet E, Brunelin J (2014) Efficacy and safety of fronto-
606 temporal transcranial random noise stimulation (tRNS) in drug-free patients with schizophrenia: a
607 case study. *Schizophr Res* 159:251-252.

608 Haq AU, Sitzmann AF, Goldman ML, Maixner DF, Mickey BJ (2015) Response of depression to
609 electroconvulsive therapy: a meta-analysis of clinical predictors. *J Clin Psychiatry* 76:1374-1384.

610 Hayward KS, Brauer SG, Ruddy KL, Lloyd D, Carson RG (2017) Repetitive reaching training combined
611 with transcranial Random Noise Stimulation in stroke survivors with chronic and severe arm paresis
612 is feasible: a pilot, triple-blind, randomised case series. *J Neuroeng Rehabil* 14:46.

613 Ho KA, Taylor JL, Loo CK (2015) Comparison of the effects of transcranial random noise stimulation
614 and transcranial direct current stimulation on motor cortical excitability. *J ect* 31:67-72.

615 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016a)
616 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing Cortical
617 Excitability. *Frontiers in human neuroscience* 10:668-668.

618 Inukai Y, Saito K, Sasaki R, Tsuiki S, Miyaguchi S, Kojima S, Masaki M, Otsuru N, Onishi H (2016b)
619 Comparison of Three Non-Invasive Transcranial Electrical Stimulation Methods for Increasing Cortical
620 Excitability. *Front Hum Neurosci* 10:668-668.

621 Jooss A, Haberbosch L, Kohn A, Ronnefarth M, Bathe-Peters R, Kozarzewski L, Fleischmann R, Scholz
622 M, Schmidt S, Brandt SA (2019) Motor Task-Dependent Dissociated Effects of Transcranial Random
623 Noise Stimulation in a Finger-Tapping Task Versus a Go/No-Go Task on Corticospinal Excitability and
624 Task Performance. *Front Neurosci* 13:161.

625 Kreuzer PM, Vielsmeier V, Poepl TB, Langguth B (2017) A Case Report on Red Ear Syndrome with
626 Tinnitus Successfully Treated with Transcranial Random Noise Stimulation. *Pain Physician* 20:E199-
627 e205.

628 Kuhn M, Mainberger F, Feige B, Maier JG, Mall V, Jung NH, Reis J, Klöppel S, Normann C, Nissen C
629 (2016) State-dependent partial occlusion of cortical LTP-like plasticity in major depression.
630 *Neuropsychopharmacol* 41:1521.

631 Liu W, Ge T, Leng Y, Pan Z, Fan J, Yang W, Cui R (2017) The Role of Neural Plasticity in Depression:
632 From Hippocampus to Prefrontal Cortex. *Neural Plast* 2017:6871089.

- 633 Loo CK, Alonzo A, Martin D, Mitchell PB, Galvez V, Sachdev P (2012) Transcranial direct current
634 stimulation for depression: 3-week, randomised, sham-controlled trial. *Br J Psychiatry* 200:52-59.
- 635 Loo CK, Sachdev P, Martin D, Pigot M, Alonzo A, Malhi GS, Lagopoulos J, Mitchell P (2010) A double-
636 blind, sham-controlled trial of transcranial direct current stimulation for the treatment of
637 depression. *Int J Neuropsychopharmacol* 13:61-69.
- 638 Loo CK, Husain MM, McDonald WM, Aaronson S, O'Reardon JP, Alonzo A, Weickert CS, Martin DM,
639 McClintock SM, Mohan A (2018) International randomized-controlled trial of transcranial Direct
640 Current Stimulation in depression. *Brain Stimul* 11:125-133.
- 641 Mammarella N, Di Domenico A, Palumbo R, Fairfield B (2017) Self-generation and positivity effects
642 following transcranial random noise stimulation in medial prefrontal cortex: A reality monitoring
643 task in older adults. *Cortex* 91:186-196.
- 644 Mancuso M, Abbruzzese L, Canova S, Landi G, Rossi S, Santarnecchi E (2017) Transcranial random
645 noise stimulation does not improve behavioral and neurophysiological measures in patients with
646 subacute vegetative-unresponsive wakefulness state (VS-UWS). *Front Hum Neurosci* 11:524.
- 647 McFadden JL, Borckardt JJ, George MS, Beam W (2011) Reducing procedural pain and discomfort
648 associated with transcranial direct current stimulation. *Brain Stimul* 4:38-42.
- 649 Moffa AH, Brunoni AR, Fregni F, Palm U, Padberg F, Blumberger DM, Daskalakis ZJ, Bennabi D,
650 Haffen E, Alonzo A (2017) Safety and acceptability of transcranial direct current stimulation for the
651 acute treatment of major depressive episodes: Analysis of individual patient data. *J Affect Disord*
652 221:1-5.
- 653 Moliadze V, Fritzsche G, Antal A (2014a) Comparing the efficacy of excitatory transcranial stimulation
654 methods measuring motor evoked potentials. *Neural plasticity* 2014:837141-837141.
- 655 Moliadze V, Fritzsche G, Antal A (2014b) Comparing the efficacy of excitatory transcranial
656 stimulation methods measuring motor evoked potentials. *Neural Plast* 2014:837141-837141.
- 657 Montagne B, Kessels RP, De Haan EH, Perrett DI (2007) The Emotion Recognition Task: a paradigm to
658 measure the perception of facial emotional expressions at different intensities. *Percept Mot Skills*
659 104:589-598.
- 660 Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. *Br J*
661 *Psychiatry* 134:382-389.
- 662 Moss F, Ward LM, Sannita WG (2004) Stochastic resonance and sensory information processing: a
663 tutorial and review of application. *Clin Neurophysiol* 115:267-281.
- 664 Mutz J, Edgcumbe DR, Brunoni AR, Fu CHY (2018) Efficacy and acceptability of non-invasive brain
665 stimulation for the treatment of adult unipolar and bipolar depression: A systematic review and
666 meta-analysis of randomised sham-controlled trials. *Neurosci Biobehav Rev* 92:291-303.
- 667 Nikolin S, Huggins C, Martin D, Alonzo A, Loo CK (2018) Safety of repeated sessions of transcranial
668 direct current stimulation: A systematic review. *Brain Stimulation* 11:278-288.
- 669 Nitsche M, Paulus W (2001) Sustained excitability elevations induced by transcranial DC motor
670 cortex stimulation in humans. *Neurology* 57:1899-1901.
- 671 Nitsche MA, Cohen LG, Wassermann EM, Priori A, Lang N, Antal A, Paulus W, Hummel F, Boggio PS,
672 Fregni F, Pascual-Leone A (2008) Transcranial direct current stimulation: State of the art 2008. *Brain*
673 *Stimul* 1:206-223.
- 674 Noda Y, Zomorodi R, Vila-Rodriguez F, Downar J, Farzan F, Cash RF, Rajji TK, Daskalakis ZJ,
675 Blumberger DM (2018) Impaired neuroplasticity in the prefrontal cortex in depression indexed
676 through paired associative stimulation. *Depress Anxiety* 35:448-456.
- 677 Palm U, Schiller C, Fintescu Z, Obermeier M, Keeser D, Reisinger E, Pogarell O, Nitsche M, Möller H-J,
678 Padberg F (2012) Transcranial direct current stimulation in treatment resistant depression: a
679 randomized double-blind, placebo-controlled study. *Brain Stimul* 5:242-251.
- 680 Palm U, Chalah MA, Padberg F, Al-Ani T, Abdellaoui M, Sorel M, Dimitri D, Creange A, Lefaucheur JP,
681 Ayache SS (2016) Effects of transcranial random noise stimulation (tRNS) on affect, pain and
682 attention in multiple sclerosis. *Restor Neurol Neurosci* 34:189-199.

683 Pavan A, Ghin F, Contillo A, Milesi C, Campana G, Mather G (2019) Modulatory mechanisms
684 underlying high-frequency transcranial random noise stimulation (hf-tRNS): A combined stochastic
685 resonance and equivalent noise approach. *Brain Stimul.*
686 Pittenger C, Duman RS (2008) Stress, depression, and neuroplasticity: a convergence of mechanisms.
687 *Neuropsychopharmacol* 33:88-109.
688 Player MJ, Taylor JL, Alonzo A, Loo CK (2012) Paired associative stimulation increases motor cortex
689 excitability more effectively than theta-burst stimulation. *Clin Neurophysiol* 123:2220-2226.
690 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev P, Martin D, Mitchell PB, Loo CK (2013)
691 Neuroplasticity in depressed individuals compared with healthy controls. *Neuropsychopharmacol*
692 38:2101.
693 Player MJ, Taylor JL, Weickert CS, Alonzo A, Sachdev PS, Martin D, Mitchell PB, Loo CK (2014)
694 Increase in PAS-induced neuroplasticity after a treatment course of transcranial direct current
695 stimulation for depression. *J Affect Disord* 167:140-147.
696 Popescu T, Krause B, Terhune DB, Twose O, Page T, Humphreys G, Cohen Kadosh R (2016)
697 Transcranial random noise stimulation mitigates increased difficulty in an arithmetic learning task.
698 *Neuropsychologia* 81:255-264.
699 Rufener KS, Ruhnau P, Heinze H-J, Zaehle T (2017) Transcranial random noise stimulation (tRNS)
700 shapes the processing of rapidly changing auditory information. *Front Cell Neurosci* 11:162.
701 Rufener KS, Geyer U, Janitzky K, Heinze HJ, Zaehle T (2018) Modulating auditory selective attention
702 by non-invasive brain stimulation: Differential effects of transcutaneous vagal nerve stimulation and
703 transcranial random noise stimulation. *Eur J Neurosci* 48:2301-2309.
704 Ruff RM, Allen CC (1996) *Ruff 2 and 7 Selective Attention Test Professional Manual*. Odessa, FL:
705 Psychological Assessment Resources, Inc.
706 Rush AJ, Trivedi MH, Wisniewski SR, Stewart JW, Nierenberg AA, Thase ME, Ritz L, Biggs MM,
707 Warden D, Luther JF (2006a) Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for
708 depression. *New England Journal of Medicine* 354:1231-1242.
709 Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, Niederehe G, Thase ME,
710 Lavori PW, Lebowitz BD, McGrath PJ, Rosenbaum JF, Sackeim HA, Kupfer DJ, Luther J, Fava M
711 (2006b) Acute and Longer-Term Outcomes in Depressed Outpatients Requiring One or Several
712 Treatment Steps: A STAR*D Report. *Am J Psychiatry* 163:1905-1917.
713 Salemi G, Vazzoler G, Ragonese P, Bianchi A, Cosentino G, Croce G, Gangitano M, Portera E,
714 Realmuto S, Fierro B, Brighina F (2019) Application of tRNS to improve multiple sclerosis fatigue: a
715 pilot, single-blind, sham-controlled study. *J Neural Transm (Vienna)*.
716 Sampaio-Junior B, Tortella G, Borriore L, Moffa AH, Machado-Vieira R, Cretaz E, da Silva AF, Fraguas
717 R, Aparicio LV, Klein I (2018) Efficacy and safety of transcranial direct current stimulation as an add-
718 on treatment for bipolar depression: a randomized clinical trial. *JAMA Psychiatry* 75:158-166.
719 Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O
720 (2003) Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants.
721 *Science* 301:805-809.
722 Schulz KF, Altman DG, Moher D (2010) CONSORT 2010 statement: updated guidelines for reporting
723 parallel group randomised trials. *BMC Med* 8:18.
724 Shalev N, De Wandell L, Dockree P, Demeyere N, Chechacz M (2018) Beyond time and space: The
725 effect of a lateralized sustained attention task and brain stimulation on spatial and selective
726 attention. *Cortex* 107:131-147.
727 Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC
728 (1998) The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation
729 of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. *J Clin Psychiatry* 59 Suppl
730 20:22-33;quiz 34-57.
731 Smith A (1991) *Symbol Digit Modalities Test*. Los Angeles, CA: Western Psychological Services.

732 Snowball A, Tachtsidis I, Popescu T, Thompson J, Delazer M, Zamarian L, Zhu T, Kadosh RC (2013)
733 Long-term enhancement of brain function and cognition using cognitive training and brain
734 stimulation. *Curr Biol* 23:987-992.
735 Szymkowicz SM, McLaren ME, Suryadevara U, Woods AJ (2016) Transcranial Direct Current
736 Stimulation Use in the Treatment of Neuropsychiatric Disorders: A Brief Review. *Psychiatr Ann*
737 46:642-646.
738 Terney D, Chaieb L, Moliadze V, Antal A, Paulus W (2008) Increasing human brain excitability by
739 transcranial high-frequency random noise stimulation. *J Neurosci* 28:14147-14155.
740 Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH,
741 Lebowitz B, McGrath PJ (2006) Evaluation of outcomes with citalopram for depression using
742 measurement-based care in STAR* D: implications for clinical practice. *Am J Psychiatry* 163:28-40.
743 Tyler SC, Conto F, Battelli L (2018) Rapid Improvement on a Temporal Attention Task within a Single
744 Session of High-frequency Transcranial Random Noise Stimulation. *J Cogn Neurosci* 30:656-666.
745 van der Groen O, Wenderoth N (2017) Random noise stimulation of the cortex: stochastic resonance
746 enhances central mechanisms of perception. *Brain Stimul* 10:e4.
747 Van der Groen O, Tang MF, Wenderoth N, Mattingley JB (2018) Stochastic resonance enhances the
748 rate of evidence accumulation during combined brain stimulation and perceptual decision-making.
749 *PLoS Comput Biol* 14:e1006301.
750 Vanneste S, Fregni F, De Ridder D (2013) Head-to-head comparison of transcranial random noise
751 stimulation, transcranial AC stimulation, and transcranial DC stimulation for tinnitus. *Front*
752 *Psychiatry* 4:158.
753 Wechsler D (2008) Wechsler Adult Intelligence Scale (4th ed.). San Antonio, TX: Pearson.
754

755 **Supplementary Materials**

756 Paired associative stimulation methods

757 Participants sat in a comfortable, relaxed position with both hands on a pillow. The
758 optimal site for eliciting motor evoked potentials (MEPs) in the right first dorsal interosseous
759 (FDI) muscle was first established and marked on the scalp. Each participant's resting motor
760 threshold (RMT) – defined as the minimum stimulus intensity to evoke MEPs of ≥ 50 μ V in
761 the relaxed FDI in 5 out of 10 consecutive trials of single-pulse TMS – was then measured.
762 TMS intensity for evoking test MEPs was adjusted individually for each participant to elicit
763 an average 1 mV response. TMS intensity for testing MEPs was limited to a maximum of
764 130% of RMT even if the actual intensity needed to elicit a 1 mV response was greater.

765 For the stimulation protocol, single-pulse TMS (130% of RMT) to the FDI
766 representation on the left motor cortex was combined with electrical stimuli (200 μ s duration,
767 300% perceptual threshold, DS7 stimulator; Digitimer Co. Ltd., Hertfordshire, UK) to the
768 right ulnar nerve proximal to the wrist. Two hundred pairs of stimuli (TMS and ulnar nerve)
769 were given at 0.25 Hz over ~13 minutes. In each pair, ulnar nerve stimulation preceded TMS
770 by 25 ms. Electrical stimuli were delivered occasionally to the right index finger during PAS.
771 Participants counted the stimuli and reported the number at the end of the session to ensure
772 sensory attention to the hand (Stefan et al., 2004). The MEPs recorded before and after PAS
773 to assess cortical excitability consisted of testing blocks of 20 MEPs at a rate of 0.1 Hz. Two
774 blocks of MEPs were recorded at baseline. A block of MEPs was recorded immediately after
775 PAS and then every 10 mins for one hour. During all stimulation, EMG from the FDI was
776 monitored to ensure muscle relaxation. MEPs were discarded if EMG showed substantial
777 muscle activity (i.e. peak-to-peak amplitude ≥ 50 μ V) in the time window prior to the TMS
778 stimuli. Additionally, block-averaged MEP amplitudes were considered outliers if they were

779 more than 4 standard deviations from the mean for active and sham tRNS conditions
780 combined.
781 EMG activity was recorded through Ag/AgCl surface electrodes over the right FDI. EMG
782 was amplified, bandpass filtered (16–1000 Hz), and digitized (2000 Hz) (Cambridge
783 Electronics Design, Cambridge, UK). TMS (Magstim 200 stimulator, Magstim Co.,
784 Whitland, UK) was applied using a 70-mm figure-of eight coil oriented with the handle
785 posterolateral, 45° to the parasagittal plane.

786 **Supplementary Table S1. Schedule of assessments.**

	Baseline	Sham-controlled phase				Open-label phase				Taper phase			
	Wk 0	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4	Wk 1	Wk 2	Wk 3	Wk 4
Session	Pre 1	1-5	6-10	11-15	16-20	21-25	26-30	31-35	36-40	41	42	43	44
<i>Mood Assessments</i>													
MADRS	X		X		X		X		X				X
BDI-II	X	X	X	X	X	X	X	X	X	X	X	X	X
CGI-S	X												
CGI-I			X		X		X		X				X
Q-LES-SF	X				X				X				X
<i>Neurophysiological Assessments</i>													
PAS	X				X				X				
<i>Neuropsychological Assessments</i>													
CVLT-II	X				X				X				
Ruff 2 & 7	X				X				X				
WAIS-IV Digit Span	X				X				X				
SDMT	X				X				X				
D-KEFS Verbal Fluency	X				X				X				
CFQ	X				X				X				

787 Wk: Week. MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-S: Clinician
788 Global Impression Severity scale, is a 7-point clinician-rated scale ranked from 1-normal to 7-extremely ill. CGI-I: Clinician
789 Global Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much
790 worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative
791 stimulation. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit
792 Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire

793 **Supplementary Table S2. MADRS mixed-effects repeated measures analyses**
 794 **using other covariates.**
 795 **Results from MERM analyses during the sham-controlled phase to examine the impact of**
 796 **medications and treatment expectations as covariates on mood outcomes (i.e. MADRS**
 797 **scores).**

	Covariate		Time		Condition		Time x Condition	
	F	p	F	p	F	p	F	p
Baseline TEQ	0.28	0.599	40.93	<0.001	0.99	0.325	1.32	0.276
Antidepressants	1.14	0.289	44.28	<0.001	2.03	0.160	1.11	0.335
Lithium	3.73	0.058	44.20	<0.001	2.24	0.140	1.14	0.327
Benzodiazepine*	2.48	0.120	44.24	<0.001	1.88	0.175	1.12	0.332
Antipsychotics	1.78	0.188	44.22	<0.001	2.15	0.147	1.12	0.332
Anticonvulsants	0.34	0.561	44.26	<0.001	2.10	0.152	1.12	0.332

798 *Participants were required to cease benzodiazepine medication use prior to commencing the trial.

799 TEQ: Treatment Expectations Questionnaire

800 Supplementary Table S3. Mood, quality of life, neuroplasticity and
 801 neuropsychological outcome measures.
 802 Results from MERM analyses during the acute daily treatment phases combined (i.e. tRNS
 803 received during the sham-controlled and open-label phases).

	Condition		Time		Time × Condition	
	F	p	F	p	F	p
<i>Mood Assessments (m, SEM)</i>						
MADRS	1.09	0.300	29.39	<0.001	0.75	0.560
BDI-II	2.38	0.128	17.60	<0.001	1.00	0.447
CGI-I	6.02	0.017	15.84	<0.001	1.72	0.173
Q-LES-SF	0.00	0.967	30.00	<0.001	1.39	0.257
<i>Neuroplasticity Assessments (m, SEM)</i>						
PAS: MEP amplitude	0.40	0.530	2.11	0.135	0.72	0.193
<i>Neuropsychological Assessments (m, SEM)</i>						
CVLT-II: Trial 1-5 total recall t-score	4.47	0.036	3.12	0.046	0.17	0.844
CVLT-II: Long delay free recall z-score	5.40	0.021	3.03	0.051	0.23	0.799
D-KEFS: Letter fluency scaled score	2.70	0.102	0.14	0.867	0.38	0.683
D-KEFS: Category fluency scaled score	1.97	0.165	0.74	0.477	1.69	0.190
D-KEFS: Category switching total scaled score	2.94	0.088	1.07	0.346	0.24	0.786
Ruff 2 & 7: Total speed t-score	2.94	0.088	3.50	0.032	0.06	0.946
Ruff 2 & 7: Total accuracy t-score	0.80	0.372	0.73	0.482	0.22	0.805
SDMT: Total correct z-score	3.58	0.063	2.80	0.065	1.11	0.335
WAIS-IV Digit Span: Total correct scaled score	17.17	<0.001	2.05	0.132	0.06	0.945
CFQ: Total score	0.20	0.659	0.12	0.891	0.45	0.639

804 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global
 805 Impression Improvement scale, is a 7-point clinician-rated scale ranked from 1-very much improved to 7-very much worse.
 806 Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire – Short Form. PAS: Paired associative stimulation.
 807 MEP: motor evoked potential. CVLT: California Verbal Learning Test. WAIS: Wechsler Adult Intelligence Scale. SDMT:
 808 Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive Function System. CFQ: Cognitive Failures Questionnaire.
 809 m: Mean. SEM: Standard error of measures

810 **Supplementary Table S4. Intention-to-treat analyses.**

811 Estimated marginal means and results from MERM analyses during the sham-controlled
 812 phase, including the following covariates: Maudsley staging parameters total score as a
 813 measure of treatment resistance, and antidepressant use. Neuroplasticity and
 814 neuropsychological outcome measures are reported using an intention-to-treat analysis
 815 approach.

	Baseline		Week 2		Week 4		Condition		Time		Time × Condition	
	Sham	Active	Sham	Active	Sham	Active	F	p	F	p	F	p
<i>Neuroplasticity Assessments (m, SEM)</i>												
PAS: MEP amplitude	1.24 (0.10)	1.21 (0.12)	-	-	1.31 (0.09)	1.40 (0.10)	0.0 8	0.7 80	1. 63	0.2 09	0. 33	0.5 70
<i>Neuropsychological Assessments (m, SEM)</i>												
CVLT-II: Trial 1-5 total recall t-score	45.7 (2.2)	48.8 (2.2)	-	-	46.3 (2.3)	49.7 (2.1)	2.2 9	0.1 33	0. 10	0.7 51	0. 01	0.9 43
CVLT-II: Long delay free recall z-score	-0.42 (0.21)	0.03 (0.21)	-	-	-0.64 (0.22)	-0.39 (0.21)	2.8 2	0.0 96	1. 93	0.1 67	0. 23	0.6 35
D-KEFS: Letter fluency scaled score	11.2 (0.7)	11.6 (0.7)	-	-	10.9 (0.7)	11.9 (0.7)	1.1 8	0.2 80	0. 00	0.9 91	0. 21	0.6 48
D-KEFS: Category fluency scaled score	10.3 (0.8)	10.9 (0.8)	-	-	9.9 (0.8)	11.7 (0.8)	1.6 4	0.2 04	0. 07	0.7 89	1. 78	0.1 87
D-KEFS: Category switching total scaled score	10.0 (0.6)	11.2 (0.6)	-	-	9.6 (0.6)	10.6 (0.6)	3.6 1	0.0 60	0. 56	0.4 54	0. 04	0.8 50
Ruff 2 & 7: Total speed t-score	47.4 (1.9)	50.6 (1.9)	-	-	51.4 (1.9)	53.6 (1.9)	2.1 7	0.1 44	2. 97	0.0 87	0. 07	0.7 89
Ruff 2 & 7: Total accuracy t-score	49.6 (2.3)	46.5 (2.3)	-	-	50.4 (2.4)	48.7 (2.3)	1.0 7	0.3 02	0. 36	0.5 47	0. 09	0.7 64
SDMT: Total correct z-score	-0.31 (0.17)	0.22 (0.18)	-	-	0.00 (0.18)	0.40 (0.17)	4.1 0	0.0 47	4. 38	0.0 39	0. 53	0.4 69
WAIS-IV Digit Span: Total correct scaled score	9.7 (0.5)	11.5 (0.5)	-	-	10.5 (0.6)	12.6 (0.5)	13. 67	<0.001	2. 50	0.1 16	0. 09	0.7 71
CFQ: Total score	50.1 (2.2)	46.6 (2.2)	-	-	49.9 (2.3)	50.0 (2.2)	0.6 1	0.4 35	0. 45	0.5 01	0. 70	0.4 06

816 MADRS: Montgomery-Asberg Depression Rating Scale. BDI-II: Beck Depression Inventory. CGI-I: Clinician Global
 817 Impression Improvement scale, is a 7-point clinician-rated scale ranked
 818 from 1-very much improved to 7-very much worse. Q-LES-SF: Quality of Life Enjoyment and Satisfaction Questionnaire –
 819 Short Form. PAS: Paired associative stimulation. MEP: motor evoked potential. CVLT: California Verbal Learning Test.
 820 WAIS: Wechsler Adult Intelligence Scale. SDMT: Symbol Digit Modalities Test. D-KEFS: Delis-Kaplan Executive
 821 Function System. CFQ: Cognitive Failures Questionnaire. m: Mean. SEM: Standard error of measures

822 Supplementary Figure S1. Treatment Expectations Questionnaire

Treatment Expectations Questionnaire – Views on DCS

Participant ID _____ Date _____ Session _____

Please answer the following questions about how effective you think DCS will be in helping improve some symptoms of depression you may be experiencing. If you are not currently experiencing the symptom, please circle NA.

1) How effective do you think DCS will be for improving your **sleep**?

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with sleep

2) How effective do you think DCS will be for reducing feelings of sadness?

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with feeling sad

3) How effective do you think DCS will be for improving your **appetite**?

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with my appetite

4) How effective do you think DCS will be for improving your **concentration/decision making**?

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with concentration/decision making

5) How effective do you think DCS will be for reducing thoughts of death or suicide?

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with thoughts of death or suicide

6) How effective do you think DCS will be for improving your **general interest in things and/or your ability to enjoy things?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with general interest/ enjoying things

7) How effective do you think DCS will be for improving your **energy level?**

1	2	3	4	5	NA
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective	I don't have problems with my energy levels

8) **OVERALL**, how effective do you think DCS will be for helping to improve the symptoms you are currently experiencing?

1	2	3	4	5
Not effective at all	Only a little bit Effective	Moderately Effective	Quite Effective	Extremely Effective

9) Are there any particular reasons why you believe DCS will or will not be effective?

END OF QUESTIONNAIRE


826 Supplementary Figure S2. tRNS Side Effects Questionnaire

Side Effect	Before	During	After	Severity*	Causality [#]
Redness anode cathode					
Tingling/Itching/Burning/Pain anode cathode					
Nausea					
Lightheadedness/Dizziness					
Headache					
Blurred Vision					
Fatigue					
Other:					

*Severity: 1 = Mild; 2 = Moderate; 3 = Severe. If participant had a side effect after the previous tRNS session, ask when it started and for how long and record in the 'Before' column.


[#]Causality: 1 = Probably Related; 2 = Possibly Related; 3 = Probably Not Related; 4 = Not Related

828 **Supplementary Figure S3. CONSORT flow diagram.**




854 **Supplementary Figure S4. Follow-up mood outcome measures.**


855 Graphs showing mood and quality of life scores (unadjusted means \pm SD) from baseline up to
856 the 9-month follow-up assessment following completion of the open-label phase. Sample
857 sizes used for the calculation of summary statistics are presented for each time-point. **A)**
858 Montgomery-Asberg Depression Rating Scale (MADRS) scores. **B)** Beck Depression
859 Inventory (BDI-II) scores. **C)** Clinician Global Impression Severity (CGI-S) at baseline, and
860 CGI-Improvement (CGI-I) scores; the CGI-S is a 7-point clinician-rated scale ranked from 1-
861 normal (not at all ill) to 7-among most extremely ill patients. The CGI-I is a 7-point clinician-
862 rated scale ranked from 1-very much improved to 7-very much worse. **D)** Quality of Life
863 Enjoyment and Satisfaction Questionnaire – Short Form scores (Q-LES-SF).




864



865



866




867

868

869 **Supplementary Figure S5. Paired associative stimulation.**

870 Group data (estimated marginal means \pm bootstrapped 95% confidence intervals) showing the
871 time course of changes in the amplitude of motor evoked potentials (MEPs) immediately
872 after the PAS conditioning stimulus. Post-PAS MEP amplitudes were normalized to pre-PAS
873 amplitudes for each participant. **A)** MEP amplitude changes at baseline, prior to the course of
874 tRNS. **B)** MEP amplitude changes following the 4-week sham-controlled phase.




875

876 **Supplementary Figure S6. Correlation between mood and neuroplasticity.**

877 There was no association between percent change in motor evoked potentials (MEPs)

878 following paired associative stimulation (PAS) and percent change in mood scores over the

879 course of the sham-controlled phase ($r = -0.02$, $p = 0.905$).



880

881